Recent advancements in computational modelling are transforming biological research, offering powerful, efficient, and cost-effective alternatives to traditional wet‑lab experiments.
Tasks that once required months in a laboratory can now be performed by computers in minutes, creating new opportunities - and challenges - for biotech stakeholders.
This three-part series explores the implications of using in silico generated data to support patentability at the European Patent Office (EPO). As computational methods become increasingly prevalent across all stages of biological research, understanding when and how to use in silico data effectively is essential for applicants seeking to maximise the technical efficiencies offered by these new methods without compromising the strength of their patent portfolio. Meanwhile, at the other end of the patent lifecycle, strategic use of in silico generated data can provide valuable new possibilities in contentious proceedings.
This series of articles addresses the key aspects of patentability: sufficiency of disclosure, novelty and inventive step. We cover practical considerations for future applications and provide strategic guidance for patent stakeholders on how to effectively make use of in silico data while avoiding common pitfalls.